FREE WEEKLY LONGEVITY BIOTECH BRIEFING
Understand Longevity Biotech Before The Field Becomes Obvious
We study it earlier. Every week I take one company through the same 25 questions and publish what I find. Including the ones that fail.
Free. Every week. Unsubscribe anytime.
39 companies assessed. 10 on the Tracker, 8 on Scout, 21 on the Watchlist. No company has ever paid to appear here. Independent, impersonal educational research. Not investment or medical advice.
Three of the twenty-five questions
Gate 7
Has this been demonstrated in humans, or only in mice?
Gate 22
Can the valuation be sourced from a filing, or is it simply asserted?
Gate 23
Could an ordinary investor actually transact at that price?
Research From a Company Builder
I accept no compensation from any company I cover, and no company has ever paid to appear in an issue. Where I hold a personal position in a company I write about, I disclose it by name at the top of that issue. I spent more than 25 years building companies and investing in private businesses, often pitched directly by their founders. After selling most of my company in 2026 I found I could not compare one longevity biotech to another honestly, because every write-up available to me had been produced by someone with a reason to be enthusiastic. So I built a checklist. Twenty-five questions, the same ones every time, each answer tied to a dated public source. Education, not stock tips or medical advice. Eric Pemper.
One Company. Five Practical Answers.
What problem is the company trying to solve?
How does its technology work?
What has been demonstrated in people?
What may the company be worth based on public information?
What evidence matters next?
This week's company is already written
Join free and it arrives in your inbox this week.
Free. Every week. Unsubscribe anytime.
EverLife Capital provides independent, impersonal educational research. It is not investment, medical, tax or legal advice. Biotechnology programs often fail, and no company discussed is guaranteed to succeed.